Marshall Wace, LLP Outlook Therapeutics, Inc. Transaction History

Marshall Wace, LLP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.91 - $2.01 $36,662 - $80,980	-40,289 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.22 - $2.03 $138,196 - $229,950	-113,276 Reduced 73.76%	40,289 $71,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.23 $195,027 - $342,449	153,565 New	153,565 $209,000
Q2 2021 Aug 13, 2021	SELL	$1.78 - $2.76 $143,861 - $223,065	-80,821 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$0.94 - $3.31 $75,971 - $267,517	80,821 New	80,821 $182,000

31.5K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $507M
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.